The "superiority" of enoxaparin for treatment of acute coronary syndromes

Pharmacotherapy

Volumn 21, Issue 10 I, 2001, Pages 1250-1252

  Noviasky, J A ^a   Gaffney, B J ^a  

^a St Elizabeth Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HEPARINIZATION; HUMAN; SHORT SURVEY; ST SEGMENT DEPRESSION;

EID: 0034786072     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.15.1250.33892     Document Type: Short Survey

References (6)

1. Antithrombotic agents in coronary artery disease
2. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis
3. A comparison of low-molecular-weight heparin with UFH for unstable coronary artery disease. The efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group
4. Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
5. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin
6. Low molecular weight heparin in acute coronary syndrome: Evidence for superior or equivalent efficacy compared with unfractionated heparin?